Assessment of platelet reactivity with anti platelet agent (clopidogrel) after two drugs formulation PLAVIX® and PLAGERINE

Abstract

Cardiovascular disease remains the main cause of mortality. Antiplatelet therapy is the main drug use in the management of coronary artery disease. Several million of people received colpidogril, however the cost of the drug that might 3-4 dollars daily for the brand company Sanofi. pharmacies start to sell cheaper generic in Indian origin. assessment of platelet function after two drugs (Plavix and plagrine) by multiple electrode platelet aggregometry (MEA) shows no difference of both drugs on the multiplate activity, this is assessed by prospective cross sectional study included 28 patients randomized to receive either Plavix or plagrine, there is no significant differences regarded the effects of some risk factors in outcome in both group Plavix and plagrine.